These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31094478)

  • 21. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin.
    Rosenfalck AM; Thorsby P; Kjems L; Birkeland K; Dejgaard A; Hanssen KF; Madsbad S
    Acta Diabetol; 2000 Mar; 37(1):41-6. PubMed ID: 10928235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Local complications of insulin administration sites and effect on diabetes management.
    Demir G; Er E; Atik Altınok Y; Özen S; Darcan Ş; Gökşen D
    J Clin Nurs; 2022 Sep; 31(17-18):2530-2538. PubMed ID: 34622517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.
    Suzuki D; Toyoda M; Kimura M; Miyauchi M; Yamamoto N; Sato H; Tanaka E; Kuriyama Y; Miyatake H; Abe M; Umezono T; Fukagawa M
    Intern Med; 2013; 52(10):1029-34. PubMed ID: 23676586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perception of Diabetic Patients Regarding Basal Bolus Insulin Injections and Outcome of its Use.
    Shahid M; Sarfraz A; Shaikh S; Mahar SA; Alam M; Shahid N
    J Coll Physicians Surg Pak; 2016 Mar; 26(3):177-81. PubMed ID: 26975946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
    Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
    Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous glucose monitoring in hemodialyzed patients with type 2 diabetes: a multicenter pilot study.
    Képénékian L; Smagala A; Meyer L; Imhoff O; Alenabi F; Serb L; Fleury D; Dorey F; Krummel T; Le Floch JP; Chantrel F; Kessler L
    Clin Nephrol; 2014 Oct; 82(4):240-6. PubMed ID: 25161114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of different blood glucose intervention plans on elderly people with type 2 diabetes mellitus combined with dementia.
    Chen Y; Wang J; Wang LJ; Lin H; Huang PJ
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2702-2707. PubMed ID: 28678332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
    Gough SC; Bhargava A; Jain R; Mersebach H; Rasmussen S; Bergenstal RM
    Diabetes Care; 2013 Sep; 36(9):2536-42. PubMed ID: 23715753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials.
    Lankisch MR; Del Prato S; Dain MP; Mullins P; Owens DR
    Prim Care Diabetes; 2016 Feb; 10(1):51-9. PubMed ID: 26150328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of biphasic insulin aspart on glucose and lipid control in patients with Type 2 diabetes mellitus.
    Lalić NM; Micić D; Antić S; Bajović L; Pantelinac P; Jotić A; Kendereski A; Dimić D; Djukić A; Mitrović M; Vujasin M
    Expert Opin Pharmacother; 2007 Dec; 8(17):2895-901. PubMed ID: 18001251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).
    Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Ahrén B; Torffvit O; Attvall S; Ekelund M; Filipsson K; Tengmark BO; Sjöberg S; Pehrsson NG
    BMJ; 2015 Oct; 351():h5364. PubMed ID: 26512041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structured self-monitoring of blood glucose regimens improve glycemic control in poorly controlled Chinese patients on insulin therapy: Results from COMPASS.
    Ji L; Su Q; Feng B; Shan Z; Hu R; Xing X; Xue Y; Yang T; Hua Y
    J Diabetes; 2017 May; 9(5):495-501. PubMed ID: 27249791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Taking a Closer Look--Continuous Glucose Monitoring in Non-Critically Ill Hospitalized Patients with Type 2 Diabetes Mellitus Under Basal-Bolus Insulin Therapy.
    Schaupp L; Donsa K; Neubauer KM; Mader JK; Aberer F; Höll B; Spat S; Augustin T; Beck P; Pieber TR; Plank J
    Diabetes Technol Ther; 2015 Sep; 17(9):611-8. PubMed ID: 25927357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.
    Ross SA; Zinman B; Campos RV; Strack T;
    Clin Invest Med; 2001 Dec; 24(6):292-8. PubMed ID: 11767232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine.
    Ohta A; Arai K; Nishine A; Sada Y; Kato H; Fukuda H; Asai S; Nagai Y; Katabami T; Tanaka Y
    Endocr J; 2013; 60(2):173-7. PubMed ID: 23047542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.
    Billings LK; Doshi A; Gouet D; Oviedo A; Rodbard HW; Tentolouris N; Grøn R; Halladin N; Jodar E
    Diabetes Care; 2018 May; 41(5):1009-1016. PubMed ID: 29483185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin-induced lipodystrophy and predisposing factors in children and adolescents with type 1 diabetes mellitus (T1DM) in a tertiary care Egyptian center.
    Elsayed S; Soliman AT; De Sanctis V; Fawzy D; Ahmed S; Alaaraj N
    Acta Biomed; 2023 Jun; 94(3):e2023078. PubMed ID: 37326270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
    Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.